Abstract
Coenzyme Q10 (CoQ10) is critical for the cell power supply in mitochondria. CoQ10 shuttles electrons from complexes I and II to complex III, and can be anti-oxdiative. Neurons require high energy for synaptic transmission and therefore the mitochondria dysfunction often leads to severe neuronal degeneration, as observed in many neurological disorders. CoQ10 supplementation has been widely used to treat aging, stroke, neuromuscular diseases, Alzheimer's disease, Parkinson’s disease, progressive supranuclear palsy, autosomal recessive cerebellar ataxias, Huntington’s disease and amyotrophic lateral sclerosis. Here we discuss a large number of preclinical and clinical trials for CoQ10 to elucidate the mechanisms underlying CoQ10 therapy. The rational applications as a therapeutic agent in neurological disorders are discussed.
Keywords: Coenzyme Q10, mitochondrial respiratory chain, neurological disorders, rational therapeutic approaches, ATP.
CNS & Neurological Disorders - Drug Targets
Title:Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
Volume: 12 Issue: 5
Author(s): Mohamed Salama, Ti-Fei Yuan, Sergio Machado, Eric Murillo-Rodriguez, Jose A. Vega, Manuel Menendez-Gonzalez, Antonio E. Nardi and Oscar Arias-Carrion
Affiliation:
Keywords: Coenzyme Q10, mitochondrial respiratory chain, neurological disorders, rational therapeutic approaches, ATP.
Abstract: Coenzyme Q10 (CoQ10) is critical for the cell power supply in mitochondria. CoQ10 shuttles electrons from complexes I and II to complex III, and can be anti-oxdiative. Neurons require high energy for synaptic transmission and therefore the mitochondria dysfunction often leads to severe neuronal degeneration, as observed in many neurological disorders. CoQ10 supplementation has been widely used to treat aging, stroke, neuromuscular diseases, Alzheimer's disease, Parkinson’s disease, progressive supranuclear palsy, autosomal recessive cerebellar ataxias, Huntington’s disease and amyotrophic lateral sclerosis. Here we discuss a large number of preclinical and clinical trials for CoQ10 to elucidate the mechanisms underlying CoQ10 therapy. The rational applications as a therapeutic agent in neurological disorders are discussed.
Export Options
About this article
Cite this article as:
Salama Mohamed, Yuan Ti-Fei, Machado Sergio, Murillo-Rodriguez Eric, Vega A. Jose, Menendez-Gonzalez Manuel, Nardi E. Antonio and Arias-Carrion Oscar, Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/18715273113129990071
DOI https://dx.doi.org/10.2174/18715273113129990071 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perinatal Exposure to Bisphenol A and Developmental Programming
of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Churg-Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature
Current Hypertension Reviews Therapeutic Potential of Stem/Progenitor Cells in Human Skeletal Muscle for Cardiovascular Regeneration
Current Stem Cell Research & Therapy HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry The Use of Carvedilol in Pediatric Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets The Role of Autophagy in the Gut Pathogens Clearance and Evasion
Current Protein & Peptide Science Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Promises of Lipid-based Drug Delivery Systems in the Management of Breast Cancer
Current Pharmaceutical Design Surrogates of Insulin Sensitivity and Indices of Cardiometabolic Profile in Obesity
Current Vascular Pharmacology Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Pompe Disease: From New Views on Pathophysiology to Innovative Therapeutic Strategies
Current Pharmaceutical Biotechnology Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets Stiff Left Atrial Syndrome; Prospects and Possibilities. Retrospective Analysis and Review of the Literature
Current Hypertension Reviews Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences
Current Pharmaceutical Design